

Figure 1-Screening Process




Figure 2 – Study Design




Figure 3 – Control Strategy




Figure 4A – ITT PFS




Figure 4B – ITT OS




Figure 5 - PFS Doublet Group

A




Figure 5 – PFS Triplet Group

B




Figure 6 – Study Flow Chart




Figure 7 – PFS Sensitivity Analysis




Figure 8A – dMMR PFS




Figure 8B – pMMR PFS




Figure 9 – ITT OS




Figure 10A – PD-L1 positive PFS




Figure 10B – PD-L1 negative PFS




Figure 11 – Study Design with Endpoints




Figure 12A – Patient Characteristics

Characteristics		CP arm (N=241)	CP+D arm (N=238)	CP+D+O arm (N=239)
Age, years	Median (range)	64 (31–85)	64 (22–84)	63 (27–86)
Geographic region,* %	Asia	28	29	28
	Non-Asia	72	71	72
Race, %	White	59	57	58
	Asian	30	30	29
	Black/African American	4	5	6
	American Indian/ Alaska Native	0	3	3
	Other or not reported	6	5	7
Ethnicity, %	Not Hispanic or Latino	90	87	86
	Hispanic or Latino	8	12	13
Disease status, %	Newly diagnosed*	48	47	48
	FIGO Stage III	5	7	5
	FIGO Stage IV	42	40	41
	Recurrent*	52	53	52
ECOG PS, %	(0) Normal activity	65	66	69
	(1) Restricted activity	35	34	31
Measurable disease at baseline, %		82	85	77

Figure 12B – Patient Characteristics

Characteristics	CP arm (N=241)	CP+D arm (N=238)	CP+D+O arm (N=239)
MMR status, [†] %			
Proficient	80	81	80
Deficient	20	19	20
PD-L1 status, [‡] %			
Positive (TAP ≥1%)	68	71	63
Negative (TAP <1%)	31	26	34
Unknown	1	3	3
HRRm status, [§] %			
HRRm	13	11	16
Non-HRRm	55	58	59
Unknown	32	31	25
Histology type at diagnosis, %			
Endometrioid	58	59	64
Serous	22	24	18
Carcinosarcoma	9	5	8
Mixed, epithelial	5	4	4
Clear cell	3	2	3
Undifferentiated	1	2	2
Mucinous or other	2	4	2
Previous chemotherapy, %	21	21	23
Previous radiotherapy, %	29	31	36
Prior surgery, %	84	86	87

Figure 13A – ITT PFS




Figure 13B– ITT OS

OS: Secondary endpoint; prespecified interim analysis




Figure 13C – ITT ORR




Figure 13D – ITT DoR




Figure 14A – ITT TFST




Figure 14B – ITT PFS2




Figure 14C – ITT TSST




Figure 15A – dMMR OS




Figure 15B – pMMR OS




Figure 16A – dMMR TFST




Figure 16B – dMMR PFS2




Figure 16D – dMMR PFS by Subgroup




Figure 16E – dMMR ORR




Figure 16F – dMMR DoR




Figure 17A – pMMR TFST




Figure 17C – pMMR TSST




Figure 17D – pMMR PFS by Subgroup




Figure 17E – pMMR ORR




Figure 17F – pMMR DoR




Figure 18A – dMMR PFS
Pre-specified exploratory analysis




Figure 18B - pMMR PFS
Pre-specified exploratory analysis




Figure 19A – ITT PFS




Figure 19B – ITT OS




Figure 20A – dMMR PFS




Figure 20B – pMMR PFS




Figure 20C – PD-L1-positive PFS

